FDA panel to review candidate for hard-to-treat tuberculosis

FDA’s Antimicrobial Drugs Advisory Committee will meet June 6 to discuss an NDA from Global Alliance for TB Drug Development (TB Alliance) for oral pretomanid (PA-824) to treat adults with pulmonary extensively drug resistant and treatment-intolerant or non-responsive multidrug-resistant tuberculosis as part of a combination regimen with Sirturo bedaquiline and linezolid.

Johnson & Johnson (NYSE:JNJ) markets Sirturo, a diarylquinoline antibiotic, to treat TB. Linezolid is a generic bacterial protein biosynthesis inhibitor...